William Blair analyst Andrew Brackmann has reiterated their neutral stance on CDNA stock, giving a Hold rating on November 1.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andrew Brackmann has given his Hold rating due to a combination of factors impacting CareDx’s financial outlook. The company reported mixed results in its third-quarter update, with revenue and volumes falling slightly short of expectations, primarily due to lower-than-anticipated kidney transplant volumes and complexities related to prior-period collections. However, there are promising signs from CareDx’s revenue cycle management initiatives, which are beginning to show success and offer potential for future revenue growth.
Despite these positive developments, there are still uncertainties, particularly regarding the draft LCD, which remains a significant concern and could affect the company’s financial model. Clarity on this issue is not expected until early 2026, making it challenging to justify an upgrade in the stock rating at this time. While there are growth drivers in place, such as the integration with Epic Aura, the lack of immediate clarity on regulatory matters leads to the decision to maintain a Hold rating until more information becomes available.
Brackmann covers the Healthcare sector, focusing on stocks such as Exact Sciences, Veracyte, and Hologic. According to TipRanks, Brackmann has an average return of 32.3% and a 68.09% success rate on recommended stocks.
In another report released on November 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $15.50 price target.